![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
SM Seiler, M Peluso, JG Tuttle, K Pryor, C Klimas, GR Matsueda and MS Bernatowicz
Department of Cardiovascular Biochemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA.
Thrombin receptor activation, by thrombin or SFLLR-containing peptides, stimulates GTPase activity in platelet and CHRF-288 membranes. Polyclonal antibodies to peptides derived from the thrombin receptor (anti-TR52-69 and anti-TR36-49), which block many of thrombin's actions on platelets and endothelial cells, also block thrombin activation of membrane GTPase (as does thrombin active site and anion-binding exosite inhibitors). Most of the receptor-activated GTPase, stimulated by both thrombin and SFLLRNP in platelet membranes, was inhibited by prior treatment with pertussis toxin or N-ethylmaleimide, suggesting that under these conditions much of the thrombin receptor-stimulated GTPase in platelet membranes is a member of the pertussis toxin-sensitive G alpha i family. In platelet membrane preparations, the peptide agonists stimulated approximately twice as much GTPase activity as stimulated by alpha-thrombin. In contrast, the membranes prepared from CHRF-288 cells showed similar maximal SFLLRNP- and alpha-thrombin-stimulated GTPase activity. Stimulation of the platelet membrane GTPase by a variety of different peptide agonists correlated with their ability to stimulate platelet aggregation. Several peptide-based agonists were more potent than the wild-type sequence. The most potent was Ser-(p-fluoro-Phe)-(2- Napthyl-Ala)-Leu-Arg-NH2, which stimulated platelet aggregation (EC50 = 80 nM) and GTPase activity (EC50 = 110 nM). The peptide YFLLRN stimulated GTPase activity but only to approximately 40% of the activity observed with optimal concentrations of other receptor agonists. YFLLRN also limited the stimulation observed with SFLLRNP in a competitive fashion, indicating that YFLLRN is a competitive partial agonist at the thrombin receptor. These studies show that the tethered- ligand receptor mediates the GTPase activation by thrombin in platelet and CHRF-288 cell membranes, and this provides a specific, reliable, and convenient cell-free assay system with which one can evaluate agonists and partial agonists.
This article has been cited by other articles:
|
|
 |
|
  F. S. London The protein kinase C inhibitor RO318220 potentiates thrombin-stimulated platelet-supported prothrombinase activity Blood, October 1, 2003; 102(7): 2472 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Faivre, K. Regnauld, E. Bruyneel, Q.-D. Nguyen, M. Mareel, S. Emami, and C. Gespach Suppression of Cellular Invasion by Activated G-Protein Subunits Galpha o, Galpha i1, Galpha i2, and Galpha i3 and Sequestration of Gbeta gamma Mol. Pharmacol., August 1, 2001; 60(2): 363 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Macfarlane, M. J. Seatter, T. Kanke, G. D. Hunter, and R. Plevin Proteinase-Activated Receptors Pharmacol. Rev., June 1, 2001; 53(2): 245 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. O'Brien, N. Prevost, M. Molino, M. K. Hollinger, M. J. Woolkalis, D. S. Woulfe, and L. F. Brass Thrombin Responses in Human Endothelial Cells. CONTRIBUTIONS FROM RECEPTORS OTHER THAN PAR1 INCLUDE THE TRANSACTIVATION OF PAR2 BY THROMBIN-CLEAVED PAR1 J. Biol. Chem., April 28, 2000; 275(18): 13502 - 13509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Swift, P. J. Sheridan, L. Covic, and A. Kuliopulos PAR1 Thrombin Receptor-G Protein Interactions. SEPARATION OF BINDING AND COUPLING DETERMINANTS IN THE Galpha SUBUNIT J. Biol. Chem., January 28, 2000; 275(4): 2627 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Andrade-Gordon, B. E. Maryanoff, C. K. Derian, H.-C. Zhang, M. F. Addo, A. L. Darrow, A. J. Eckardt, W. J. Hoekstra, D. F. McComsey, D. Oksenberg, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor PNAS, October 26, 1999; 96(22): 12257 - 12262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Ahn, C. Foster, G. Boykow, L. Arik, A. Smith-Torhan, D. Hesk, and M. Chatterjee Binding of a Thrombin Receptor Tethered Ligand Analogue to Human Platelet Thrombin Receptor Mol. Pharmacol., February 1, 1997; 51(2): 350 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
BrianD. Blackhart, K. Emilsson, D. Nguyen, W. Teng, ArnoldJ. Martelli, S. Nystedt, J. Sundelin, and RobertM. Scarborough Ligand Cross-reactivity within the Protease-activated Receptor Family J. Biol. Chem., July 12, 1996; 271(28): 16466 - 16471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Faruqi, E. J. Weiss, M. J. Shapiro, W. Huang, and S. R. Coughlin Structure-Function Analysis of Protease-activated Receptor 4 Tethered Ligand Peptides. DETERMINANTS OF SPECIFICITY AND UTILITY IN ASSAYS OF RECEPTOR FUNCTION J. Biol. Chem., June 23, 2000; 275(26): 19728 - 19734. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
